First Wave BioPharma Inc. (NASDAQ: FWBI) is a biotech company with a focus on the gastrointestinal domain. Despite coming leaps and bounds within this specialist field, the company still awaits its breakthrough, which may come a lot sooner than the market anticipates.
First Wave BioPharma to Participate in JP Morgan’s Investment Conference
The recent news with regard to First Wave BioPharma Inc. (FWBI) is its spot on JP Morgan’s BIO Partnering Conference, which will take place in the first weeks of January. The event will not only give exposure to investors regarding the company’s fundamental strengths but will also highlight its technical progress, in terms of gastrointestinal diseases. This sort of direct exposure to the company could potentially open it up to significant investment opportunities, and shed light on its stock fundamentals. The management appears optimistic about the initiative, given its confidence in its strengths.
Rough Year for FWBI
FWBI’s participation in JP Morgan’s high-profile bio event comes as much-needed positive news after the company took a tremendous beating throughout most of 2022. The year saw FWBI stock plunge from $35 to below $0.80, with consistent failure to deliver, in terms of its ongoing trial candidates. Recently, in November, one positive update for First Wave was an application filing for an Investigational New Drug. This would hold promise considering its focus on targeted and non-systematic gastrointestinal treatments, a domain which FWBI holds immense mastery over. Therefore, this very much keeps the company within the game at yet, and far from being written off.
First Wave BioPharma has faced quite a few setbacks this year, but it remains positive as to its future prospects. Moreover, it continues to work towards the development of promising gastrointestinal diseases. Additionally, its participation in JPM’s investment conference may bring to it much-needed exposure from the markets.